Home » ISTA PHARMA BEGINS CLINICAL TRIALS OF XIBROM
ISTA PHARMA BEGINS CLINICAL TRIALS OF XIBROM
ISTA Pharmaceuticals is initiating Phase III clinical trials of once-daily formulation of Xibrom for the treatment of ocular pain and inflammation following cataract surgery.
The FDA has already approved the twice-daily Xibrom for the treatment of ocular inflammation and reduction of ocular pain following cataract surgery.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
07May
-
14May
-
30May